256 related articles for article (PubMed ID: 6290955)
1. [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
Onkologie; 1982 Aug; 5 Suppl():34-41. PubMed ID: 6290955
[TBL] [Abstract][Full Text] [Related]
2. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
[TBL] [Abstract][Full Text] [Related]
3. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].
Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599
[TBL] [Abstract][Full Text] [Related]
4. [Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
Wander HE; Nagel GA; Blossey HC
Onkologie; 1982 Aug; 5 Suppl():28-33. PubMed ID: 6215600
[TBL] [Abstract][Full Text] [Related]
5. ACTH and cortisol plasma levels in cancer patients treated with medroxyprogesterone acetate at high dosages.
Papaleo C; Carella C; Zito GA; Figlia A; Capuano F; Amato G
Chemioterapia; 1984 Aug; 3(4):220-2. PubMed ID: 6099752
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer.
Nagel GA; Wander HE; Blossey HC
Cancer Res; 1982 Aug; 42(8 Suppl):3442s-3444s. PubMed ID: 6123383
[TBL] [Abstract][Full Text] [Related]
7. [Value of hormone therapy in metastasizing breast cancer].
Samonigg H
Wien Med Wochenschr; 1985 Dec; 135(23-24):602-7. PubMed ID: 2937208
[TBL] [Abstract][Full Text] [Related]
8. [Hormonal control of disseminated breast cancer].
Voznyĭ EK; Meshcheriakova NG; Biakhov MIu; Vasiuta NIu
Sov Med; 1990; (6):94-7. PubMed ID: 2144368
[No Abstract] [Full Text] [Related]
9. [Plasma lipoprotein fractions in high-dose medroxyprogesterone acetate therapy in metastatic breast cancer].
Brockerhoff P; Grill HJ; Holzer A; Kreienberg R; Pollow K; Schicketanz KH; Schwarz V; Rathgen GH
Gynakol Rundsch; 1991; 31(4):189-200. PubMed ID: 1839014
[TBL] [Abstract][Full Text] [Related]
10. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
[TBL] [Abstract][Full Text] [Related]
11. [Combined drug/hormone therapy in metastatic breast cancer with vincristine, adriamycin, cyclophosphamide and high dose medroxyprogesterone acetate--VAC-MAP. Preliminary results of a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
Wander HE; Nagel GA; Blossey HC; Kordilla F; Stamm S; Matthressen W; Weiss J
Onkologie; 1982 Aug; 5 Suppl():8-12. PubMed ID: 6752794
[TBL] [Abstract][Full Text] [Related]
12. [Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study].
Wander HE; Kleeberg UR; Essers U; Blossey HC; Nagel GA
Onkologie; 1987 Oct; 10(5):321-3. PubMed ID: 2960938
[No Abstract] [Full Text] [Related]
13. Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
Pannuti F; Martoni A; Piana E; Tomasi L; Grieco A; Farris A; Saccani F; Baroni M
Chemioterapia; 1984 Aug; 3(4):211-5. PubMed ID: 6241846
[TBL] [Abstract][Full Text] [Related]
14. [Adjuvant hormone therapy of primary breast cancer. Review of the literature].
Focan C
Rev Med Liege; 1991 May; 46(5):270-8. PubMed ID: 1830160
[No Abstract] [Full Text] [Related]
15. Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.
Pannuti F; Martoni A; Fruet F; Strocchi E; Di Marco AR
Eur J Cancer (1965); 1980; Suppl 1():93-8. PubMed ID: 6459237
[No Abstract] [Full Text] [Related]
16. [Hormone therapy in metastasized breast cancer. Criteria for establishing indications and implementing high-dose medroxyprogesterone acetate therapy].
Possinger K; Wagner H; Langecker P; Schmid L; Willich S; Wilmanns W
Fortschr Med; 1987 Jul; 105(22):421-4. PubMed ID: 2958397
[No Abstract] [Full Text] [Related]
17. On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.
Petru E; Schmähl D
Klin Wochenschr; 1987 Oct; 65(20):959-66. PubMed ID: 2963170
[TBL] [Abstract][Full Text] [Related]
18. [The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer].
Kadota K; Wada T; Watatani M; Houjou T; Mori N; Yasutomi M
Gan To Kagaku Ryoho; 1991 May; 18(6):983-7. PubMed ID: 1827574
[TBL] [Abstract][Full Text] [Related]
19. [Endocrine therapy of breast cancer].
Jonat W; Maass H
Zentralbl Gynakol; 1987; 109(10):617-27. PubMed ID: 2956805
[TBL] [Abstract][Full Text] [Related]
20. [Progestational agents and bone metastasis in breast cancer].
Leriche N; Bonneterre J
Bull Cancer; 1997 Sep; 84(9):891-4. PubMed ID: 9435812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
